Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal clinical trial of JSP191 in MDS/AML transplant

Next Previous
Trial Profile

A pivotal clinical trial of JSP191 in MDS/AML transplant

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 10 Jan 2023 According to a Jasper Therapeutics media release, company does not have any near-term plans to initiate this study , the Company will continue to work with the U.S. Food and Drug Administration, the transplant community and potential partners to explore development pathways and ensure briquilimab remains ready for this study.
  • 10 Nov 2022 According to a Jasper Therapeutics media release, the company held a Type B meeting with the FDA and agreed with the FDA to submit a trial protocol that will allow the initiation of this study.
  • 28 Apr 2022 According to a Jasper Therapeutics media release, the company looks forward to completing the study protocol for review with the FDA and launching this registrational study early next year

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top